Grifols, S.A. (NASDAQ:GRFS) Shares Bought by Black Creek Investment Management Inc.

Black Creek Investment Management Inc. lifted its position in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) by 1.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,251,960 shares of the biotechnology company's stock after buying an additional 141,615 shares during the period. Grifols makes up about 4.0% of Black Creek Investment Management Inc.'s holdings, making the stock its 11th biggest holding. Black Creek Investment Management Inc. owned 1.64% of Grifols worth $83,715,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. R Squared Ltd acquired a new stake in Grifols in the 4th quarter valued at $28,000. GAMMA Investing LLC boosted its position in shares of Grifols by 44.5% in the fourth quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company's stock worth $37,000 after buying an additional 1,527 shares during the period. Blue Trust Inc. grew its stake in shares of Grifols by 254.0% in the fourth quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company's stock valued at $52,000 after buying an additional 4,970 shares in the last quarter. Envestnet Portfolio Solutions Inc. acquired a new position in Grifols during the 4th quarter worth approximately $77,000. Finally, Raymond James Financial Inc. purchased a new position in Grifols in the 4th quarter worth approximately $91,000.

Grifols Stock Up 0.7 %

Shares of Grifols stock traded up $0.05 during trading hours on Friday, hitting $7.08. 500,119 shares of the company's stock traded hands, compared to its average volume of 1,212,512. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. Grifols, S.A. has a twelve month low of $5.79 and a twelve month high of $9.96. The stock has a 50 day simple moving average of $7.49 and a 200-day simple moving average of $7.83. The company has a market cap of $4.87 billion, a PE ratio of 6.05 and a beta of 0.41.

Analysts Set New Price Targets

Separately, Morgan Stanley started coverage on shares of Grifols in a research note on Wednesday, February 12th. They set an "overweight" rating on the stock.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.